Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG NIVAHL Trial

被引：0
|
作者：
Broeckelmann, Paul J. [1 ]
Buehnen, Ina [1 ]
Herhaus, Peter [2 ]
Meissner, Julia [3 ]
Trautmann, Karolin [4 ]
Mueller, Horst [1 ]
Fuchs, Michael [1 ]
von Tresckow, Bastian [5 ]
Borchmann, Peter [1 ]
Engert, Andreas [1 ]
Behringer, Karolin [1 ]
机构：
[1] Uniklin Koln, Klin Innere Med 1, Deutsch Hodgkin Studiengrp GHSG, Cologne, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Innere Med 3, Munich, Germany
[3] Uniklin Heidelberg, Med 5, Heidelberg, Germany
[4] Tech Univ Dresden, Uniklin Carl Gustav Carus Dresden, Dresden, Germany
[5] Uniklin Essen, Klin Hamatol & Stammzelltransplantat, Deutsch Hodgkin Studiengrp GHSG, Essen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
318
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [31] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
    Bischoff, H.
    Scherpereel, A.
    Antonia, S.
    Bautista, Y.
    Grossi, F.
    Kowalski, D.
    Zalcman, G.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mans-Field, A.
    Popat, S.
    Sun, X.
    Padilla, B.
    Aanur, P.
    Daumont, M.
    Bennett, B.
    McKenna, M.
    Baas, P.
    PNEUMOLOGIE, 2021, 75 : S17 - S17
  • [32] Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment
    Nolla, Kyle
    Benjamin, David J.
    Cella, David
    NATURE REVIEWS UROLOGY, 2023, 20 (07) : 420 - 433
  • [33] Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment
    Kyle Nolla
    David J. Benjamin
    David Cella
    Nature Reviews Urology, 2023, 20 : 420 - 433
  • [34] Patients′ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
    Reck, M.
    Granados, A. L. O. Ortega
    de Marinis, F.
    Shen, Q.
    Boklage, S. H.
    Dabrowski, C.
    Cho, L.
    Meyers, O.
    ANNALS OF ONCOLOGY, 2023, 34
  • [35] Patients' perspective on tolerability of dostarlimab in NSCLC: patient-reported outcomes from the Phase II PERLA trial
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Shen, Qin
    Boklage, Susan
    Dabrowski, Christine
    Cho, Lillian
    Meyers, Oren
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 130 - 130
  • [36] The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050
    Paty, Jean
    Sandin, Rickard
    Reisman, Arlene
    Wu, Yi-Long
    Migliorino, Maria Rita
    Zhou, Xiangdong
    Cheng, Ying
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Corral, Jesus
    Pluzanski, Adam
    Linke, Rolf
    Meyers, Oren
    Mok, Tony S.
    FUTURE ONCOLOGY, 2021, 17 (07) : 783 - 794
  • [37] Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma
    Engert, Andreas
    Taylor, Fiona
    Bennett, Bryan
    Hirji, Ishan
    Cocks, Kim
    McDonald, Jeffrey
    Mann, Erin
    Kato, Kazunobu
    Cella, David
    BLOOD, 2016, 128 (22)
  • [38] Patient-Reported Quality of Life Outcomes After De-Escalated Chemoradiation for HPV-Positive Oropharyngeal Carcinoma: Findings From a Phase II Trial
    Hegde, John V.
    Shaverdian, Narek
    Daly, Megan E.
    Felix, Carol
    Garst, Jordan
    Meshman, Jessica
    Kelly, Karen
    Chen, Allen M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E35 - E35
  • [39] A SYSTEMATIC LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES IN PHASE III RANDOMIZED CONTROLLED TRIALS OF HEPATOCELLULAR CARCINOMA IN A FIRST-LINE SETTING
    Attri, S.
    Singh, B.
    VALUE IN HEALTH, 2023, 26 (06) : S35 - S35
  • [40] Patient-Reported Quality of Life and Functional Outcomes in A Phase II Blinded Randomized Trial of Hippocampal Avoidance Whole Brain Radiotherapy for Brain Metastases
    Chen, C. Y.
    Lin, H. J.
    Yang, W. C.
    Hsu, F. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E166 - E166
12345